PL3166615T3 - Chelatowane tiofosforanowe polimery kwasu nukleinowego do zastosowania w połączeniu z inhibitorem polimerazy hbv do leczenia zakażeń wirusem zapalenia wątroby typu b i wirusem zapalenia wątroby typu d - Google Patents
Chelatowane tiofosforanowe polimery kwasu nukleinowego do zastosowania w połączeniu z inhibitorem polimerazy hbv do leczenia zakażeń wirusem zapalenia wątroby typu b i wirusem zapalenia wątroby typu dInfo
- Publication number
- PL3166615T3 PL3166615T3 PL15818148.7T PL15818148T PL3166615T3 PL 3166615 T3 PL3166615 T3 PL 3166615T3 PL 15818148 T PL15818148 T PL 15818148T PL 3166615 T3 PL3166615 T3 PL 3166615T3
- Authority
- PL
- Poland
- Prior art keywords
- hepatitis
- phosphorotiotated
- chelated
- treatment
- nucleic acid
- Prior art date
Links
- 108700024845 Hepatitis B virus P Proteins 0.000 title 1
- 229940123066 Polymerase inhibitor Drugs 0.000 title 1
- 208000002672 hepatitis B Diseases 0.000 title 1
- 208000029570 hepatitis D virus infection Diseases 0.000 title 1
- 150000007523 nucleic acids Chemical class 0.000 title 1
- 102000039446 nucleic acids Human genes 0.000 title 1
- 108020004707 nucleic acids Proteins 0.000 title 1
- 229920000642 polymer Polymers 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462022846P | 2014-07-10 | 2014-07-10 | |
| US201462091943P | 2014-12-15 | 2014-12-15 | |
| PCT/CA2015/050626 WO2016004525A1 (en) | 2014-07-10 | 2015-07-07 | Methods for the treatment of hepatitis b and hepatitis d virus infections |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3166615T3 true PL3166615T3 (pl) | 2024-02-19 |
Family
ID=55063440
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL15818148.7T PL3166615T3 (pl) | 2014-07-10 | 2015-07-07 | Chelatowane tiofosforanowe polimery kwasu nukleinowego do zastosowania w połączeniu z inhibitorem polimerazy hbv do leczenia zakażeń wirusem zapalenia wątroby typu b i wirusem zapalenia wątroby typu d |
Country Status (34)
| Country | Link |
|---|---|
| US (1) | US9603865B2 (https=) |
| EP (1) | EP3166615B1 (https=) |
| JP (2) | JP2017521433A (https=) |
| KR (2) | KR20170029577A (https=) |
| CN (2) | CN106659730A (https=) |
| AU (1) | AU2015286199B2 (https=) |
| BR (1) | BR112017000320B1 (https=) |
| CA (1) | CA2954182C (https=) |
| CL (1) | CL2017000008A1 (https=) |
| CU (1) | CU20170001A7 (https=) |
| CY (1) | CY1126361T1 (https=) |
| DK (1) | DK3166615T3 (https=) |
| DO (1) | DOP2017000002A (https=) |
| EA (1) | EA036745B1 (https=) |
| EC (1) | ECSP16097355A (https=) |
| ES (1) | ES2963814T3 (https=) |
| FI (1) | FI3166615T3 (https=) |
| HK (1) | HK1231402A1 (https=) |
| HR (1) | HRP20231400T1 (https=) |
| HU (1) | HUE064449T2 (https=) |
| IL (1) | IL249660B (https=) |
| LT (1) | LT3166615T (https=) |
| MD (1) | MD4760C8 (https=) |
| MX (1) | MX381042B (https=) |
| MY (1) | MY178087A (https=) |
| PH (1) | PH12017500010B1 (https=) |
| PL (1) | PL3166615T3 (https=) |
| PT (1) | PT3166615T (https=) |
| RS (1) | RS64833B1 (https=) |
| SG (1) | SG11201700073PA (https=) |
| SI (1) | SI3166615T1 (https=) |
| SM (1) | SMT202300380T1 (https=) |
| TW (1) | TWI766831B (https=) |
| WO (1) | WO2016004525A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20211783A1 (es) * | 2018-11-08 | 2021-09-08 | Aligos Therapeutics Inc | Polimeros oligonucleotidos que inhiben el transporte de antigenos y metodos |
| US11166976B2 (en) * | 2018-11-08 | 2021-11-09 | Aligos Therapeutics, Inc. | S-antigen transport inhibiting oligonucleotide polymers and methods |
| US20210189392A1 (en) * | 2019-12-12 | 2021-06-24 | Aligos Therapeutics, Inc. | S-antigen transport inhibiting oligonucleotide polymers and methods |
| WO2021223398A1 (zh) * | 2020-05-07 | 2021-11-11 | 西安新通药物研究股份有限公司 | 治疗肝病的晶型及其应用 |
| CN113620993A (zh) * | 2020-05-07 | 2021-11-09 | 西安新通药物研究股份有限公司 | 甲磺酸帕拉德福韦d晶型及其应用 |
| CN114057816B (zh) * | 2020-07-30 | 2025-02-11 | 浙江柏拉阿图医药科技有限公司 | 富含腺嘌呤硫代磷酸酯化寡核苷酸及其抗肝炎病毒的应用 |
| WO2022109129A1 (en) * | 2020-11-20 | 2022-05-27 | Aligos Therapeutics, Inc. | Conjugates of s-antigen transport inhibiting oligonucleotide polymers having enhanced liver targeting |
| TW202245809A (zh) | 2020-12-18 | 2022-12-01 | 美商詹森藥物公司 | 用於治療b型肝炎病毒感染之組合療法 |
| WO2022152869A1 (en) | 2021-01-15 | 2022-07-21 | Janssen Sciences Ireland Unlimited Company | Use of oligonucleotides for individuals with hepatic impairment |
| WO2022261046A1 (en) * | 2021-06-07 | 2022-12-15 | Antios Therapeutics, Inc. | Compositions and methods of treating hepatitis d and hepatitis b/hepatitis d co-infections with phosphoramidate clevudine prodrugs |
| JP2024527380A (ja) | 2021-07-09 | 2024-07-24 | グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー３）、リミテッド | 腎機能障害を有する個体へのオリゴヌクレオチドの使用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5482836A (en) * | 1993-01-14 | 1996-01-09 | The Regents Of The University Of California | DNA purification by triplex-affinity capture and affinity capture electrophoresis |
| BR0314236A (pt) | 2002-09-13 | 2005-08-09 | Replicor Inc | Formulação de oligonucleotìdeo, composição farmacêutica, kit, composto antiviral, preparação de oligonucleotìdeo e métodos para seleção de um oligonucleotìdeo antiviral para uso como um agente antiviral, para profilaxia ou tratamento de uma infecção viral em um paciente, para tratamento profilático de câncer causado por oncovìrus, para identificação de um composto que altera a ligação de um oligonucleotìdeo a pelo menos um componente viral, para purificação da ligação de oligonucleotìdeos a pelo menos um componente viral e para enriquecimento de oligonucleotìdeos a partir de um agrupamento de oligonucleotìdeos |
| US9474793B2 (en) * | 2005-02-22 | 2016-10-25 | The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Vaccines and methods for prevention and treatment of drug-resistant HIV-1 and hepatitis B virus |
| BR112013003875B1 (pt) | 2010-08-20 | 2021-10-05 | Replicor Inc | Composições farmacêuticas compreendendo complexo de quelato de oligonucleotídeo, formulação de oligonucleotídeo, e usos |
| WO2012058210A1 (en) * | 2010-10-29 | 2012-05-03 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA) |
| WO2012075114A2 (en) * | 2010-12-01 | 2012-06-07 | Ablitech, Inc. | Nucleic acid-polymer conjugates and uses thereof |
| SMT202100319T1 (it) * | 2012-05-18 | 2021-09-14 | Replicor Inc | Composizioni e metodi del complesso oligonucleotide chelato polipeptidico |
| AR091065A1 (es) * | 2012-05-18 | 2014-12-30 | Replicor Inc | Una formulacion farmaceutica que comprende un quelato de oligonucleotidos antiviral para el tratamiento de una infeccion antiviral |
| SG11201501255PA (en) * | 2012-08-30 | 2015-03-30 | Replicor Inc | Methods for the treatment of hepatitis b and hepatitis d infections |
-
2015
- 2015-07-07 CN CN201580037179.0A patent/CN106659730A/zh active Pending
- 2015-07-07 CN CN202111146395.2A patent/CN113750112A/zh active Pending
- 2015-07-07 RS RS20231031A patent/RS64833B1/sr unknown
- 2015-07-07 EP EP15818148.7A patent/EP3166615B1/en active Active
- 2015-07-07 MD MDA20170014A patent/MD4760C8/ro active IP Right Grant
- 2015-07-07 MX MX2017000053A patent/MX381042B/es unknown
- 2015-07-07 SG SG11201700073PA patent/SG11201700073PA/en unknown
- 2015-07-07 SI SI201531976T patent/SI3166615T1/sl unknown
- 2015-07-07 PT PT158181487T patent/PT3166615T/pt unknown
- 2015-07-07 LT LTEPPCT/CA2015/050626T patent/LT3166615T/lt unknown
- 2015-07-07 WO PCT/CA2015/050626 patent/WO2016004525A1/en not_active Ceased
- 2015-07-07 HU HUE15818148A patent/HUE064449T2/hu unknown
- 2015-07-07 PL PL15818148.7T patent/PL3166615T3/pl unknown
- 2015-07-07 FI FIEP15818148.7T patent/FI3166615T3/fi active
- 2015-07-07 MY MYPI2017700005A patent/MY178087A/en unknown
- 2015-07-07 EA EA201790160A patent/EA036745B1/ru unknown
- 2015-07-07 BR BR112017000320-1A patent/BR112017000320B1/pt not_active IP Right Cessation
- 2015-07-07 SM SM20230380T patent/SMT202300380T1/it unknown
- 2015-07-07 KR KR1020177003538A patent/KR20170029577A/ko not_active Ceased
- 2015-07-07 DK DK15818148.7T patent/DK3166615T3/da active
- 2015-07-07 JP JP2017501004A patent/JP2017521433A/ja active Pending
- 2015-07-07 HR HRP20231400TT patent/HRP20231400T1/hr unknown
- 2015-07-07 HK HK17105180.0A patent/HK1231402A1/zh unknown
- 2015-07-07 AU AU2015286199A patent/AU2015286199B2/en not_active Ceased
- 2015-07-07 KR KR1020237015821A patent/KR102734495B1/ko active Active
- 2015-07-07 PH PH1/2017/500010A patent/PH12017500010B1/en unknown
- 2015-07-07 ES ES15818148T patent/ES2963814T3/es active Active
- 2015-07-07 CA CA2954182A patent/CA2954182C/en active Active
- 2015-07-08 US US14/794,129 patent/US9603865B2/en not_active Expired - Fee Related
- 2015-07-13 TW TW104122636A patent/TWI766831B/zh active
-
2016
- 2016-12-20 IL IL249660A patent/IL249660B/en unknown
-
2017
- 2017-01-03 EC ECIEPI201697355A patent/ECSP16097355A/es unknown
- 2017-01-03 CL CL2017000008A patent/CL2017000008A1/es unknown
- 2017-01-03 DO DO2017000002A patent/DOP2017000002A/es unknown
- 2017-01-05 CU CUP2017000001A patent/CU20170001A7/es unknown
-
2020
- 2020-04-20 JP JP2020074639A patent/JP6922030B2/ja not_active Expired - Fee Related
-
2023
- 2023-11-07 CY CY20231100626T patent/CY1126361T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| LT3166615T (lt) | Chelatiniai fosforotioato nukleorūgšties polimerai, skirti panaudoti derinyje su hbv polimerazės inhibitoriumi hepatito b ir hepatito d virusinių infekcijų gydymui | |
| IL325517A (en) | Engineered megacannolyases specific for recognition sequences in the hepatitis B virus genome | |
| IL272820B (en) | The history of sulfamoylpyrrolamide and their use as drugs to treat jaundice b | |
| IL245436A0 (en) | New dihydroquinolizinones for the treatment and prevention of hepatitis b virus infection | |
| DK3546585T3 (da) | Nukleinsyrer med en modificeret intron til brug i behandlingen af hyperbilirubinæmi | |
| IL244431A0 (en) | Pharmacy methods and preparations for the treatment of hepatitis b virus infection | |
| ZA201701643B (en) | Pyrrolopyrimidines for use in influenza virus infection | |
| IL237173A0 (en) | Methods for treating hepatitis b and hepatitis d infections | |
| IL254243A0 (en) | Hepatitis C virus polymerase inhibitors. | |
| SI3137078T1 (sl) | Zdravljenje okužbe s hepatitis delta virusom | |
| IL255366B (en) | Reagents for the treatment of hepatitis B infection and their use | |
| PL3463469T3 (pl) | Kombinacja ledipaswiru i sofosbuwiru do zastosowania w leczeniu zakażeń wirusem zapalenia wątroby typu b u ludzi | |
| WO2014160088A3 (en) | Treating hepatitis b virus infections | |
| EP3271371A4 (en) | Nucleotide derivatives which are hcv inhibitors for use in the treatment of hepatitis c | |
| IL286484B (en) | Reagents for treatment of hepatitis b virus (hbv) infection and use thereof | |
| TH1601002531A (th) | กรดนิวคลีอิกและวิธีการสำหรับการตรวจหาเชื้อก่อโรคและจุลินทรีย์ที่เป็นประโยชน์ | |
| TH1601001266A (th) | วิธีการและองค์ประกอบทางเภสัชกรรมสำหรับการบำบัดการติดเชื้อไวรัสตับอักเสบ b | |
| AU2015901617A0 (en) | Reagents for treatment of hepatitis B virus (HBV) infection and use thereof |